BioSpace News Archive

Cesca Therapeutics Inc. announced that the Company will release its financial results for the second quarter ended June 30, 2019 on Tuesday, August 13, 2019 after the close of trading.

X4 Pharmaceuticals, Inc. announced that on August 2, 2019 the Compensation Committee of X4’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,000 shares of its common stock to 4 new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

Magenta Therapeutics announced that the Company is scheduled to present at the Wedbush PacGrow Healthcare Conference on August 13, 2019 at 3:05 p.m. ET at the Parker New York in New York City.

The global affinity chromatography reagents market is expected to post a CAGR close to 10% during the period 2019-2023, according to the latest market research report by Technavio.

Favorable overall safety, tolerability, and pharmacokinetic profile of LHF-535 for Lassa fever demonstrated in first-in-human study

Ricardo Estape, M.D., a robotic gynecologic oncology surgeon specializing in robotic single incision surgeries from South Miami Gynecology Oncology Group, led the completion of the GLP studies.

The Parkinson’s Foundation announced the addition of three new Centers of Excellence to its global network of expert care providers for people with Parkinson’s disease (PD).

HiberCell announced the appointment of Colin Goddard to the company’s Board of Directors.

Industry veterans from Thermo Fisher and Agilent join the board